Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in PH Associated With Diastolic Heart Failure (DILATE)
NCT01172756Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jul 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of riociguat in pulmonary hypertension (PH), sponsored by Bayer. Primary endpoint: Mean Pulmonary Artery Pressure at 6 hours. Started Jul 2010; status: terminated.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT01172756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172756.